Nav1.7

– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to initiate mid-year – Phase 3 azetukalner bipolar depression program planned for clinical trial initiation mid-year – Early-stage portfolio advancing with Kv7 and Nav1.7 IND filings anticipated in 2025 – Neurocrine collaboration achieves milestone with initiation of Phase 1 study of Nav1.2/Nav1.6 inhibitor – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2024. “We expect the next 12 to 24 months will represent a catalyst-rich period for Xenon as we continue to advance our deep pipeline of promising late- and early-stage programs across multiple neurological and neuropsychiatric indications. The anticipated readout from our Phase 3 study in focal onset seizures signifies an important inflection point and could set the stage for our first potential commercial product launch in epilepsy. In addition to building upon our growing leadership in the epilepsy community, we firmly believe that azetukalner has broad potential in neuropsychiatric indications based upon strong mechanistic and scientific rationale, and we are pleased to be enrolling patients in our Phase 3 MDD program, with plans to now initiate a registrational program studying the use of azetukalner in bipolar depression,” said Ian Mortimer, President and Chief Executive Officer of Xenon. “We also expect multiple regulatory filings in 2025 coming out of our early-stage portfolio – which includes Kv7 and Nav1.7 candidates that are progressing through IND-enabling studies – to support the initiation of first-in-human trials across multiple targets. In addition, we are pleased to confirm a promising Nav1.2/Nav1.6 sodium channel inhibitor discovered in Xenon labs has progressed into a Phase 1 study as part of our collaboration with Neurocrine Biosciences, triggering a milestone payment to us,” stated Mr. Mortimer. Business Highlights and Anticipated Milestones Azetukalner Clinical Development Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD) and bipolar depression (BPD). Epilepsy Programs Phase 3 X-TOLE2/3 azetukalner clinical studies in FOS continue to advance, with the first topline data readout anticipated in the second half of 2025. Phase 3 X-ACKT clinical study continues to enroll patients and is intended to support potential regulatory submissions in an additional epilepsy indication of PGTCS. Building upon more than 700+ patient-years of data to date from the ongoing X-TOLE open-label extension (OLE) study, Xenon continues to generate long-term scientific evidence supporting azetukalner’s compelling efficacy and safety profile, with approximately one in three patients on drug for at least 36 months achieving seizure freedom for a period of one year or longer. Xenon continues to present data at leading medical conferences, including the upcoming medical congresses of the American Society for Experimental Neurotherapeutics (ASENT) and the American Academy of Neurology (AAN) taking place in the first half of this year. Neuropsychiatric Programs X-NOVA2, the first of three planned Phase 3 clinical trials evaluating azetukalner in patients with MDD is currently enrolling patients, and X-NOVA3 is expected to initiate mid-year. Xenon announces plans for a Phase 3 BPD program with initiation of the first of two azetukalner clinical studies in bipolar I and bipolar II depression expected by mid-year. Initiation of this program is based on a strong scientific rationale – supported by promising clinical data with azetukalner and the Kv7 mechanism in MDD and preclinical research examining the genetic links between BPD and Kv7 and evidence of Kv7 downregulation in BPD – as well as a large unmet medical need. Patient enrollment in the investigator-sponsored Phase 2 proof-of-concept study of azetukalner in MDD led by Icahn School of Medicine at Mount Sinai is complete, and topline results are anticipated in the first half of 2025. Early-Stage Pipeline: Next Generation Ion Channel Modulators Xenon continues to expand its portfolio by leveraging its extensive expertise to discover and develop potassium and sodium channel therapeutics, with the goal of filing multiple INDs, or equivalent, in 2025. IND-enabling work is underway with multiple Kv7 development candidates. Kv7 may have utility in a broad range of therapeutic indications including seizures, pain, and neuropsychiatric disorders, such as MDD and BPD. IND-enabling work is underway with a lead Nav1.7 development candidate. Nav1.7 is an important pain-related target, based on strong human genetic validation, that may represent a new class of medicines without the limitations of opioids. The Company expects a lead candidate within its Nav1.1 program will enter IND-enabling studies in 2025. Pre-clinical data suggests that targeting Nav1.1 could potentially address the underlying cause and symptoms of Dravet Syndrome. Partnered Program As part of Xenon’s ongoing collaboration with Neurocrine Biosciences to develop treatments for epilepsy, NBI-921355, a Nav1.2 and Nav1.6 sodium channel inhibitor in development for the potential treatment for certain types of epilepsy, has progressed into a Phase 1 clinical study in healthy adult participants, triggering an anticipated $7.5 million milestone payment to Xenon. Corporate Xenon announced that Sherry Aulin plans to step down as Chief Financial Officer due to personal reasons. Ms. Aulin is expected to continue to serve as CFO until June 30, 2025, and then act as an advisor through the end of August to ensure a smooth transition. “Sherry has made invaluable contributions to the organization over the last decade and was instrumental in helping build Xenon as we evolved from a discovery organization to what is now a late-stage clinical organization readying for our first potential drug approval and commercial launch,” said Mr. Mortimer. “On behalf of the Board and our entire Xenon team, I want to thank Sherry for her successful leadership as CFO and commitment to ensure a smooth transition at this important time for the company.” “While I am stepping down for personal reasons, I remain excited about Xenon’s future, as it enters this transformational period driving towards commercialization, as well as the significant impact Xenon’s therapeutics could potentially have on the lives of patients around the world. It has been a privilege to serve as CFO of Xenon, and I am truly honored to have worked alongside such a talented team, and very confident that Xenon is positioned for success,” said Ms. Aulin. Fourth Quarter & Full Year Financial Results Cash and cash equivalents and marketable securities were $754.4 million as of December 31, 2024, compared to $930.9 million as of December 31, 2023. Based on current operating plans, including the completion of the azetukalner Phase 3 epilepsy studies and supporting late-stage clinical development of azetukalner in MDD and BPD, Xenon anticipates having sufficient cash to fund operations into 2027. As of December 31, 2024, there were 76,416,086 common shares and 2,173,081 pre-funded warrants outstanding. Research and development expenses were $59.5 million for the fourth quarter of 2024, and $210.4 million for the year ended 2024, compared to $41.1 million and $167.5 million for the same periods in 2023, respectively. The increase in research and development expenses for the year was primarily attributable to the azetukalner program and increased expenses related to the ongoing Phase 3 epilepsy clinical trials, the initiation of the first Phase 3 MDD clinical trial, as well as manufacturing activities to support current and future clinical trials and a potential NDA submission, and increased personnel-related costs due to an increase in employee headcount and higher stock-based compensation expense. General and administrative expenses were $18.0 million for the fourth quarter of 2024, and $68.9 million for the year ended 2024, compared to $12.6 million and $46.5 million for the same periods in 2023, respectively. The increase in general and administrative expenses for the year was primarily attributable to personnel-related costs due to an increase in employee headcount and higher stock-based compensation expense, and an increase in professional and consulting fees. Other income was $7.9 million for the fourth quarter of 2024, and $40.9 million for the year ended 2024, compared to $8.7 million and $31.4 million for the same periods in 2023. The increase in other income for the year was primarily attributable to higher interest income. Net loss was $65.7 million for the fourth quarter of 2024, and $234.3 million for the year ended 2024, compared to $44.7 million and $182.4 million for the same periods in 2023, respectively. The increase in net loss for the year was primarily attributable to higher research and development expenses driven by the azetukalner program, as well as increased personnel-related costs and stock-based compensation expense across the organization, partially offset by an increase in interest income. Conference Call Information Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its fourth quarter and full year 2024 results. A listen-only webcast can be accessed on the Investors section of the Xenon website, with a replay available following the event. Participants can access the conference call by dialing (800) 715-9871 or (646) 307-1963 for international callers and referencing conference ID 8120798. About Azetukalner Phase 3 Epilepsy Program Xenon’s Phase 3 epilepsy program includes three Phase 3 clinical trials in focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS). Designed closely after the Phase 2b X-TOLE clinical trial, the Phase 3 X-TOLE clinical trials are multicenter, randomized, double-blind, placebo-controlled studies evaluating the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered orally with food as adjunctive treatment in approximately 360 patients with FOS per study. The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the 12-week double-blind period (DBP) of azetukalner compared to placebo. X-ACKT is a multicenter, randomized, double-blind, placebo-controlled study evaluating the clinical efficacy, safety, and tolerability of 25 mg of azetukalner administered with food as adjunctive treatment in approximately 160 patients with PGTCS. The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the 12-week DBP of azetukalner compared to placebo. Upon completion of the DBP in the Phase 3 epilepsy studies, eligible patients may enter an OLE study for up to three years. About Azetukalner Phase 3 MDD Program Xenon’s Phase 3 MDD program includes three multicenter, randomized, double-blind, placebo-controlled clinical trials to evaluate the clinical efficacy, safety, and tolerability of 20 mg of azetukalner administered orally with food over the 6-week double-blind period (DBP) as monotherapy treatment in approximately 450 patients with moderate-to-severe major depressive disorder (MDD) per study. The primary efficacy endpoint is the change from baseline in the HAM-D17 score at week 6 in patients who received azetukalner compared to placebo. Upon completion of the DBP, eligible patients may enter an OLE study for up to 12 months. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com. Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical trials; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners’ product candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in our azetukalner and other pipeline and development programs, including the anticipated filing of INDs and NDAs; the timing and results of our interactions with regulators; our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates; and anticipated timing of topline data readout from our clinical trials of azetukalner. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators’ product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation or completion of clinical trials; the impact of market, industry, and regulatory conditions on clinical trial enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors: Chad Fugere Vice President, Investor Relations (857) 675-7275 investors@xenon-pharma.com For Media: Colleen Alabiso Senior Vice President, Corporate Affairs (617) 671-9238 media@xenon-pharma.com Source: Xenon Pharmaceuticals Inc.

iStock/ Deagreez Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a growing number of alternative approaches. Their ultimate uptake, however, remains to be seen. When Vertex Pharmaceuticals won FDA approval for Journavx last month, it opened a new era in a therapeutic space recently fraught with suffering, controversy and thousands of avoidable deaths. Eighty million people in the U.S. suffer from acute pain every year, according to William Blair analyst Myles Minter, who told BioSpace in an email that many of these patients will be treated with opioids. After non-steroidal anti-inflammatory drugs (NSAID) and acetaminophen, standard of care options are varying strengths of opioids, Minter said. “There is a clear treatment gap whereby pain severity for several individuals is not at the threshold of requiring high efficacy opioid therapy [yet] but is beyond that of ‘rescue’ or over the counter NSAID/acetaminophen options.” Minter believes Journavx could fill this gap—and be a “potential game-changer” in addressing the opioid crisis in the U.S. There are also several other non-opioid analgesics in biopharma’s pipeline. Still, there are hurdles to overcome—including price. A single Journavx pill costs $15.50, bringing a patient’s daily spend to $31. Opioids, in comparison, are leagues cheaper at $0.50 for a generic, non-branded pill, Minter said. Of course, this doesn’t take into account larger healthcare and societal costs that opioids accrue because of their addictive risk. The Centers for Disease Control and Prevention (CDC) pegged the cost of opioid use disorder and related fatalities in the U.S. at over $1 trillion in 2017. But Rohan Jotwani, an academic anesthesiologist and pain medicine specialist at Weill Cornell Medicine, isn’t hopeful that insurers will look at this bigger picture. “I would like to believe a story that, because this is an anti-opioid medication, it’s going to get clearance from insurance companies a little faster,” Jotwani said last month on a call hosted by Truist Securities. “But that being said, I’ve also had many fights with insurance companies on all kinds of medications.” Blocking Signals When broken down to a simplistic, molecular level, pain is essentially a series of signals sent from pain receptors located at different parts of the body through a complex network of neurons to, ultimately, the central nervous system. To transmit these signals, nerve cells are studded with voltage-gated sodium channels , which open and close in response to certain stimuli. In turn, the action of these channels results in a series of reactions, which propagate, channel to channel, nerve to nerve, to bring the pain signals to the appropriate region of the brain. Opioids, arguably the most famous—and infamous—form of analgesic, work by binding to certain receptors found on nerves, in turn disrupting the cascade of pain signals through the body. This mechanism is effective at dampening pain but can also be dangerous. Opioid receptors are also found in the reward system area of the brain, and overuse of the drug could lead to feelings of euphoria, which in turn could spin out of control and result in addiction. According to the National Institute on Drug Abuse, nearly 74,000 people died from an overdose of synthetic opioids in 2022. That same year, the CDC estimated that the age-adjusted rate of drug overdose rates from synthetic opioids other than methadone jumped almost 23 times from 2013 levels. Journavx is different. An ion channel blocker, Vertex’s drug selectively targets peripheral nerves, thereby eliminating the potential for addiction. Designed to be taken orally twice a day, it works by selectively targeting and blocking a specific subset of these sodium channels called NaV1.8, preventing pain signals from reaching the spinal cord. “Before Journavx there has not been a non-opioid alternative approved for outpatient use,” Minter said. And Journavx may be only the beginning for this new class of pain medicines as several other biotechs seek to follow in Vertex’s footsteps. One of these is Latigo Bio, which launched in February 2024 with $135 million in starting funds to advance its own oral NaV1.8 blocker LTG-001. At the time of its debut, CEO Desmond Padhi told BioSpace LTG-001 has the potential to be the best in its drug class. Whether Latigo will pose a credible challenge to Vertex remains to be seen, however. The start-up just recently wrapped Phase I testing for LTG-001, launching a Phase II trial last month in patients who have undergone surgical molar extraction. Earlier this month, the company stated in an SEC filing that it is now targeting up to $150 million in new funding. Taking a different approach to non-opioid analgesia is Sangamo Therapeutics. The California–based biotech is working on a very early gene editor that leverages zinc finger technology to target the SCN9A gene, which encodes for NaV1.7, a related type of voltage-gated sodium channel. In May 2023, Sangamo unveiled promising preclinical data at the American Society of Gene & Cell Therapy meeting, demonstrating that the investigational gene editor, ST-503, can strongly repress SCN9A repression in various animal and cell models. The company filed an Investigational New Drug application in November 2024 for ST-503 for the treatment of intractable pain due to idiopathic small fiber neuropathy. Also advancing an editing approach to ion channel blockage is Cambridge-based Korro Bio. According to a company filing , Korro’s pain program targets and edits the mRNA encoding for NaV1.7, in turn dampening the activity of the protein and achieving similar effects as small-molecule channel blockers. The biotech is optimizing and screening potential oligonucleotides that it can use to carry out these RNA edits. Alternative Pathways Aside from preventing the propagation of signals through a network of ion channels, there are many other pathways that can elicit pain relief. A growing number of biotechs are exploring these avenues to develop non-addictive analgesics. One of these, Lexicon Pharmaceuticals, is developing pilavapadin (also known as LX9211), an oral small-molecule compound for neuropathic pain. The neuropathic pain distinction is “essential,” CEO Mike Exton told BioSpace in an email . Acute pain, for which Journavx is indicated, is often “localized and resolves quickly” and typically arises after an injury or surgery. Neuropathic pain, in contrast, “is centrally driven and complex, is often chronic and results from nerve damage” that requires more specialized and long-term care, Exton said. “In the U.S. alone, approximately 9 million people are currently diagnosed with diabetic peripheral neuropathic pain (DPNP),” a number expected to reach 13 million by 2035, according to Exton. These patients face a crucial shortage of non-opioid options, of which there have been no new approvals in more than 20 years, he said. Lexicon hopes to fill this gap with pilavapadin, which works by targeting the adapter-associated kinase 1 (AAK1) protein. AAK1 is highly expressed in the central nervous system and while its exact role in the pain pathology has yet to be elucidated, studies have shown that knocking it out can substantially alleviate neuropathic pain and other neurological disorders. Indeed, Lexicon’s own preclinical studies have found that mice without the AAK1 gene were more resistant to induced neuropathic pain, according to Exton. The biotech is currently running a Phase IIb trial of pilavapadin in DPNP, topline data from which are expected in the first quarter of this year. Thereafter, Lexicon expects to move quickly, leveraging the FDA’s Fast Track designation to accelerate its time to the market. “We are positioned to be the first oral non-opioid approved for neuropathic pain,” Exton said. Earlier in the drug development process is South Rampart Pharma, which is advancing a non-opioid painkiller that not only avoids the addictive potential of opioids but also sidesteps the toxicity typical of other analgesics. The candidate, dubbed SRP-001, is a compound that, inside the body, is broken down into AM404, a known metabolite of acetaminophen that exerts analgesic effects on the brain. Unlike acetaminophen, however, SRP-001 does not produce byproducts that are toxic to the liver, CEO Hernan Bazan told BioSpace in an email. The asset is also classified as a non-NSAID, meaning it is “devoid of the kidney and gastrointestinal damage with overuse,” Hernan said, opening up the possibility of higher or prolonged dosing. Hernan added that unlike Journavx—and other sodium channel blockers in development—SRP-001 “addresses pain centrally” in the central nervous system. “That difference could matter for complex or refractory pain states where peripheral mechanisms alone aren’t sufficient.” An oral formulation of SRP-001 recently cleared Phase I in acute pain, and South Rampart is now working to push it into Phase II development. The biotech is also developing intravenous and topical versions of SRP-001. These are hardly the only players in the crowded non-opioid space. Algiax Pharmaceuticals unveiled promising Phase IIa data for its small-molecule GABA A activator AP-325, and Xgene Pharmaceutical is working on XG005, an investigational pill that in December 2024 cleared Phase IIb . Closer still to the market is Tris Pharma, which last month posted a Phase III win for cebranopadol, an agonist of the nociceptin/orphanin FQ peptide and µ-opioid peptide receptors. Tris is planning an NDA submission for cebranopadol later this year. A Place for Opioids? Even with Journavx’s approval—and with the flood of non-opioid pain relief treatments in development—analysts don’t expect opioids to fade from relevance any time soon. “We don’t think opioids will be eliminated here as they are still effective pain management agents when used correctly,” William Blair’s Minter said. Jotwani, on the Truist call, expressed similar sentiments. Opioids, he said, still have a place in the clinic, especially in cases where other avenues of analgesia fail. “I don’t see this as an either-or,” he said. “I don’t see this as either you get suzetrigine [Journavx] or you get opioids. I see this as a ‘we give probably the suzetrigine first because it has less side effects and has a less addictive pro no addictive pro if that fails, we have opioids as a backup.’” This approach closely mirrors current medical practice, where patients after a surgery are already readied to receive the powerful painkiller oxycodone. But doctors still “make sure they try the Tylenol and the NSAIDs first,” according to Jotwani. Because of their different modes of action, as well as efficacy and safety pro both opioids and non-opioid treatments can comprise a holistic pain management approach, he said. “If the patients do well, I don’t see a reason why a surgeon would say ‘let’s not send them home with suzetrigine instead of the opioid,” Jotwani continued. “If the patient needs an opioid, they will call the office and the surgeon will escalate.” Aside from their analgesic efficacy, cost could also help to maintain the place of opioids in medical care. In a February 2025 report , the Institute for Clinical and Economic Review found that Journavx’s current price tag is “slightly cost-saving relative to opioid therapy, while producing greater health benefits,” but at many times the price of a generic opioid, the new drug has an uphill battle with insurers, Jotwani said. “They will want the patients to try oxycodone before they’ll pay for” these alternatives, he said.

SOUTH SAN FRANCISCO, CA, USA I February 04, 2025 I SiteOne Therapeutics, Inc., a clinical-stage biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions involving hyperexcitability of the peripheral nervous system, today announced positive phase 1 clinical trial results for STC-004, its lead Na V 1.8 inhibitor for the non-opioid treatment of pain. “These compelling phase 1 results reinforce the potential of STC-004 as a transformative, non-opioid solution for pain management,” said John Mulcahy, Ph.D., President and CEO of SiteOne Therapeutics. “The data demonstrate target engagement at low, once-daily doses, validating our approach and advancing our mission to provide patients with safer, more effective pain relief. With these results in hand, we are focused on rapidly advancing STC-004 into Phase 2 trials in the second half of this year.” STC-004 is an oral, highly selective Na V 1.8 inhibitor under development for the treatment of acute and chronic peripheral pain. The phase 1 study, STC-004-CS-001, evaluated the safety, tolerability and pharmacokinetics of the candidate in single ascending dose (SAD) and multiple ascending dose (MAD) arms. Pharmacokinetic data showed rapid absorption with a half-life appropriate for once-daily oral dosing. Exposure was proportional and demonstrated low variability across the dose range. STC-004 was well-tolerated at all doses tested. Pharmacodynamic testing performed during the MAD cohorts using the Cold Pressor Test (CPT) model of experimental pain supported target engagement across the dose range tested. Statistically significant increases in the Pain Tolerance Threshold (PTT) were observed. These findings are consistent with target engagement of the human Na V 1.8 channel at low, once-daily oral doses, demonstrating significant analgesic potential. About SiteOne Therapeutics SiteOne Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of highly selective small molecule inhibitors targeting Na V 1.7, Na V 1.8, and other ion channels to treat pain, cough and other conditions involving hyperexcitability of the peripheral nervous system. Since its inception, SiteOne has been dedicated to the development of safe and effective pain therapeutics without the significant addiction potential and side effects of opioids. The company is also advancing additional novel drug candidates that exhibit precise selectivity for individual ion channel subtypes to treat other sensory hyperexcitability disorders such as chronic cough and chronic ocular surface pain. For more information, visit www.siteonetherapeutics.com . SOURCE: SiteOne Therapeutics